Insulet Securities Class Action Lawsuit
Analysis based on 21 articles · First reported Aug 10, 2026 · Last updated Aug 24, 2026
The class action lawsuit and the underlying manufacturing issues have negatively impacted Insulet's stock price, with significant drops following the disclosure of the Medical Device Corrections. The legal proceedings and potential liability could further pressure the company's valuation and investor sentiment in the near term.
Insulet Corporation, a medical device company known for its Omnipod insulin delivery systems, is facing a securities class action lawsuit alleging violations of the Securities Exchange Act of 1934. The lawsuit, filed in the U.S. District Court for the District of Massachusetts, claims that Insulet made false and misleading statements regarding its manufacturing controls and procedures. Specifically, the company allegedly failed to maintain appropriate manufacturing controls, creating safety risks for customers and leading to voluntary Medical Device Corrections for certain Omnipod products. The class period runs from February 21, 2025 to May 26, 2026. On March 12, 2026, Insulet disclosed a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods, causing its stock to fall nearly 7%. On May 26, 2026, another correction was announced for additional Omnipod products, leading to a further stock decline of more than 5%. Several law firms, including DJS Law Group, Rosen Law Firm, and Robbins Geller Rudman & Dowd LLP, are reminding investors of the August 31, 2026 lead plaintiff deadline. The lawsuit seeks to recover losses for investors who purchased Insulet securities during the class period.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard